Trulicity is indicated for the treatment of adults with
insufficiently controlled type 2 diabetes mellitus as an
adjunct to diet and exercise:
Adverse event reporting information can be found at the bottom of the page.
Not registered? Register now
Trulicity (dulaglutide) is a once weekly injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) with proven efficacy in reducing HbA1c in adults with type 2 diabetes.1 The REWIND study demonstrated cardiovascular benefits for Trulicity reducing the risk of major cardiovascular events, in a broad type 2 diabetes population.2
This live webinar will take place on 10 September 2021 at 13:00. The session faculty will consist of Dr Shahzada Khan (Chair) and the key-note speaker Dr Akhila Mallipedhi. Dr Mallipedhi will consider the clinical trial data supporting Trulicity (dulaglutide) in treating people with type 2 diabetes2 and examine the practicalities of initiating this medication in the same population. There will also be a look at the Trulicity (dulaglutide) higher dose data provided by the AWARD-11 trial3. Throughout the webinar there will be ample opportunity to submit questions to be answered during the live Q&A following the broadcast.
GP Principle, Newham, East London
Consultant in Diabetes, Prince Phillip Hospital, Llanelli
Sign up to all DiabetesontheNet journals